A detailed history of Sherbrooke Park Advisers LLC transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 28,429 shares of FOLD stock, worth $276,329. This represents 0.07% of its overall portfolio holdings.

Number of Shares
28,429
Holding current value
$276,329
% of portfolio
0.07%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$9.55 - $12.09 $271,496 - $343,706
28,429 New
28,429 $304 Million
Q1 2024

May 15, 2024

BUY
$11.43 - $14.24 $534,946 - $666,460
46,802 New
46,802 $551 Million

Others Institutions Holding FOLD

About AMICUS THERAPEUTICS, INC.


  • Ticker FOLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 280,497,984
  • Market Cap $2.73B
  • Description
  • Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...
More about FOLD
Track This Portfolio

Track Sherbrooke Park Advisers LLC Portfolio

Follow Sherbrooke Park Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sherbrooke Park Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sherbrooke Park Advisers LLC with notifications on news.